- Home
- QTTB
as 07-26-2024 4:00pm EST
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 244.8M | IPO Year: | N/A |
| Target Price: | $62.25 | AVG Volume (30 days): | 132.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -32.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.24 - $42.98 | Next Earning Date: | 08-05-2024 |
| Revenue: | $354,000 | Revenue Growth: | -93.39% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Q32 Bio Inc. Common Stock (QTTB)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Alloway Paul | QTTB | See Remarks | Mar 25 '24 | Sell | $24.21 | 268 | $6,488.28 | 2,596 | SEC Form 4 |
| Michaud Charles Jr | QTTB | See Remarks | Mar 25 '24 | Sell | $24.20 | 75 | $1,815.00 | 927 | SEC Form 4 |
| Michaud Charles Jr | QTTB | See Remarks | Jan 3 '24 | Sell | $0.57 | 1,708 | $975.27 | 11,598 | SEC Form 4 |
| Alloway Paul | QTTB | See Remarks | Jan 3 '24 | Sell | $0.57 | 7,280 | $4,120.48 | 28,036 | SEC Form 4 |
| TZIANABOS ARTHUR | QTTB | Director | Jan 1 '24 | Sell | $0.57 | 13,037 | $7,445.43 | 128,778 | SEC Form 4 |
Latest Q32 Bio Inc. Common Stock News
QTTB Breaking Stock News: Dive into QTTB Ticker-Specific Updates for Smart Investing
PR Newswire
18 days ago
Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis
PR Newswire
a month ago
Q32 Bio Joins Russell 3000® Index
Simply Wall St.
a month ago
Q32 Bio Inc.'s (NASDAQ:QTTB) last week's 15% decline must have disappointed private equity firms who have a significant stake
Business Wire
2 months ago
Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
GlobeNewswire
2 months ago
Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
GlobeNewswire
2 months ago
Share buy-back programme - week 23
Simply Wall St.
2 months ago
Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?
Reuters
2 months ago
Japan's service sector mood hits nearly 2-year low in May
Compare QTTB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QTTB Q32 Bio Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.